title: ODAC panel gives nod to Bexxar.
authors.forename: Ken
authors.initials: K
authors.lastname: Garber
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; C422802:ibritumomab tiuxetan; C119496:tositumomab I-131